

Antonio Tello-Montoliu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6385708/publications.pdf>

Version: 2024-02-01

29
papers

599
citations

759233

12
h-index

610901

24
g-index

33
all docs

33
docs citations

33
times ranked

1054
citing authors

#	ARTICLE	IF	CITATIONS
1	Global longitudinal strain assessment of cardiac function and extravascular lung water formation after diving using semi-closed circuit rebreather. <i>European Journal of Applied Physiology</i> , 2022, 122, 945-954.	2.5	4
2	Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7113.	4.1	7
3	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 749-757.	0.6	38
4	TRimetazidine as an Agent to affect clopidogrel Response: The TRACER Study. <i>Cardiology and Therapy</i> , 2019, 8, 229-237.	2.6	3
5	Prevalence of clopidogrel resistance™ in a selected population of patients undergoing elective percutaneous coronary intervention at a tertiary cardiovascular centre in Trinidad: the POINT pilot study. <i>Open Heart</i> , 2019, 6, e000841.	2.3	11
6	Chronic Kidney Disease and Third-Generation P2Y ₁₂ Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 295-302.	2.0	2
7	Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease. <i>Minerva Medica</i> , 2019, 110, 410-418.	0.9	4
8	Disparities in the Estimation of Glomerular Filtration Rate According to Cockcroft-Gault, Modification of Diet in Renal Disease ⁴ , and Chronic Kidney Disease Epidemiology Collaboration Equations and Relation With Outcomes in Patients With Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	16
9	Acute Myocarditis with Infarct-like Presentation in a Pediatric Population: Role of Cardiovascular Magnetic Resonance. <i>Pediatric Cardiology</i> , 2018, 39, 51-56.	1.3	10
10	Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry. <i>European Journal of Cardiovascular Nursing</i> , 2017, 16, 696-703.	0.9	10
11	Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. <i>Platelets</i> , 2016, 27, 777-783.	2.3	5
12	Response to ECG, July 2015. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 718.	0.6	0
13	ECG de julio de 2015. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 627.	1.2	0
14	Respuesta al ECG de julio de 2015. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 718.	1.2	0
15	ECG, July 2015. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 627.	0.6	0
16	Pharmacodynamic Effects of Cangrelor on Platelet P2Y ₁₂ Receptor-Mediated Signaling in Prasugrel-Treated Patients. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 426-434.	2.9	28
17	Impaired Responsiveness to the Platelet P2Y ₁₂ Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1005-1014.	2.8	155
18	Abstract 16668: The Effects of Dabigatran on Fibrin Network Structure and Lysis: A Simple Technique to Monitor Efficacy of Treatment?. <i>Circulation</i> , 2014, 130, .	1.6	0

#	ARTICLE	IF	CITATIONS
19	Successful pregnancy and delivery on prasugrel treatment: considerations for the use of dual antiplatelet therapy during pregnancy in clinical practice. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 348-351.	2.1	34
20	Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 14-17.	2.1	14
21	Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. <i>Thrombosis and Haemostasis</i> , 2013, 110, 777-784.	3.4	7
22	Prasugrel. <i>Advances in Cardiology</i> , 2012, 47, 39-63.	2.7	3
23	Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 297-299.	2.1	7
24	Influencia de los polimorfismos de CYP2C19 en la reactividad plaquetaria y el pronóstico en una población no seleccionada de pacientes con síndrome coronario agudo sin elevación del ST. <i>Revista Española De Cardiología</i> , 2012, 65, 219-226.	1.2	16
25	Cigarette Smoking Is Associated With a Dose-Response Effect in Clopidogrel-Treated Patients With Diabetes Mellitus and Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 293-300.	2.9	48
26	Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 119-133.	4.1	14
27	Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 905-912.	2.9	17
28	Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. <i>Future Cardiology</i> , 2011, 7, 381-402.	1.2	13
29	Antiplatelet therapy: thrombin receptor antagonists. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 658-671.	2.4	34